Recruitment. Patients with a histological diagnosis of well-differentiated GEP, thoracic and unknow primary NETs that are anticipated to be treated with cabozantinib and lanreotide will be approached for consideration for study entry. Patients will be approached only once the appropriate official notification has been received by the chief investigator that the trial is open for recruitment.
